Cinchona lancifolia para Inflamación
Cinchona lancifolia — 4 estudios científicos revisados
Moderate¿Sirve Cinchona lancifolia para inflamación?
La cinchonina posee propiedades antiinflamatorias que pueden ayudar a reducir la respuesta inflamatoria sistémica, especialmente en contextos relacionados con dietas altas en grasas [PMID 38031797].
Compuestos activos involucrados: Alcaloides, Flavonoides, Terpenos, Cinchonina, Quinolina, Compuestos fenólicos
Evidencia Científica
Los siguientes estudios han investigado la relación entre Cinchona lancifolia y inflamación:
Cinchonine: A Versatile Pharmacological Agent Derived from Natural Cinchona Alkaloids.
BACKGROUND: Cinchonine is one of the Cinchona alkaloids that is commercially extracted from the Peruvian bark of Cinchona officinalis L. (Family: Rubiaceae). It is also obtained in much lower quantities from other species of Cinchona, such as Cinchona calisaya, Cinchona succirubra, and Cinchona pubescens, and in some other plants, such as Remijia peruviana. Cinchonine has been historically used as an anti-malarial agent. It also has a wide range of other biological properties, including anti-cancer, anti-obesity, anti-inflammatory, anti-parasitic, antimicrobial, anti-platelet aggregation, and
PubMed: 38031797Glycyrrhizin alleviates the toxicity of hydroxychloroquine in treating oral lichen planus by occupying heat shock protein 90 alpha.
BACKGROUND: Oral lichen planus (OLP) is a common chronic inflammatory disease with the potential of malignant transformation. Hydroxychloroquine (HCQ), derived from quinine originating from Cinchona spp. bark, is a commonly prescribed off-label for OLP. However, it lacks robust evidence-based medicine practice, as well as theoretical guidance for its pharmacodynamic targets and for mitigating adverse reactions. PURPOSE: To compare the efficacy of HCQ with first-line treatment prednisone for treating severe erosive OLP and to identify compatible phytomedicine that is reasonably available based
PubMed: 39550918Artemisinin-hydroxychloroquine combination from traditional antimalarial medicine attenuates pulmonary fibrosis via PI3K/AKT/GSK3β-mediated inhibition of epithelial-mesenchymal transition.
ETHNOPHARMACOLOGICAL RELEVANCE: Artemisinin and hydroxychloroquine, derived respectively from Artemisia annua L. (Qinghao) and Cinchona calisaya Wedd., have been widely used for centuries to treat malaria and inflammatory disorders. In addition to their antimalarial activity, these compounds exhibit multifunctionality, including anti-inflammatory, antifibrotic, and immunomodulatory effects. Although preliminary studies suggested that the artemisinin-hydroxychloroquine (AH) combination may attenuate idiopathic pulmonary fibrosis (IPF), its underlying mechanisms remain poorly understood. AIM OF
PubMed: 41076144Medicinal plants, human health and biodiversity: a broad review.
Biodiversity contributes significantly towards human livelihood and development and thus plays a predominant role in the well being of the global population. According to WHO reports, around 80 % of the global population still relies on botanical drugs; today several medicines owe their origin to medicinal plants. Natural substances have long served as sources of therapeutic drugs, where drugs including digitalis (from foxglove), ergotamine (from contaminated rye), quinine (from cinchona), and salicylates (willow bark) can be cited as some classical examples.Drug discovery from natural sources
PubMed: 25001990Seguridad y Precauciones
La seguridad en el uso de Cinchona lancifolia debe abordarse con extrema cautela debido a la presencia de alcaloides quinolínicos, los cuales poseen una ventana terapéutica estrecha. En el caso de mujeres embarazadas y en periodo de lactancia, el uso de esta planta está contraindicado o debe ser estrictamente supervisado por profesionales médicos. Los alcaloides de la familia Cinchona, como la cinchonina y la quinina, pueden atravesar la barrera placentaria y la barrera hematoencefálica, lo que representa un riesgo potencial para el desarrollo fetal y la salud del lactante. No existe evidencia suficiente que garantice la inocuidad de estos compuestos durante la gestación, por lo que se recomienda evitar su consumo para prevenir posibles efectos teratogénicos o toxicidad sistémica en el neonato. En niños menores de 12 años, su administración no está recomendada debido a la inmadurez de sus sistemas metabólicos, especialmente el hepático y el renal, lo que incrementa el riesgo de acumulación de metabolitos tóxicos. En cuanto a las interacciones farmacológicas, la Cinchona lancifolia puede interactuar peligrosamente con fármacos que afectan la coagulación, como la warfarina, debido a que ciertos alcaloides pueden alterar la agregación plaquetaria o la dinámica de la coagulación sanguínea.
Otras plantas estudiadas para Inflamación
Perfil completo: Ver todos los usos y evidencia de Cinchona lancifolia →